161 related articles for article (PubMed ID: 36304630)
41. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
Poullin P; Bornet C; Veyradier A; Coppo P
Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
[TBL] [Abstract][Full Text] [Related]
42. Pernicious Anemia Presenting as a Mimicker of Thrombotic Thrombocytopenic Purpura.
Alzarkali O; Lee JH; Bower K
Cureus; 2023 May; 15(5):e39080. PubMed ID: 37332426
[TBL] [Abstract][Full Text] [Related]
43. [Frontline clinical practice for thrombotic thrombocytopenic purpura].
Miyakawa Y
Rinsho Ketsueki; 2020; 61(9):1331-1337. PubMed ID: 33162533
[TBL] [Abstract][Full Text] [Related]
44. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Elverdi T; Eskazan AE
Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the efficacy and safety of caplacizumab versus placebo in thrombotic thrombocytopenic purpura: a meta-analysis and systematic review based on randomized controlled trials.
Chen B; Li X; Xiao D; Raimundo RD; Zhou R; Lei Y
Ann Transl Med; 2022 Jun; 10(12):657. PubMed ID: 35845542
[TBL] [Abstract][Full Text] [Related]
46. Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.
Al-Husban N; Al-Kuran O
J Med Case Rep; 2018 Jun; 12(1):147. PubMed ID: 29855343
[TBL] [Abstract][Full Text] [Related]
47. Thrombotic Thrombocytopenic Purpura: A Rare Cause of Severe Acute Kidney Injury.
Najar H; Tuider L; Kukkar V; Quasem M
Cureus; 2022 Apr; 14(4):e24221. PubMed ID: 35602841
[TBL] [Abstract][Full Text] [Related]
48. Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.
Cardesa-Salzmann TM; Stephan B; Simon A; Furtwängler R; Schöndorf D; Heine S; Torfah E; Lux M; Meyer S; Graf N
Clin Case Rep; 2022 May; 10(5):e05902. PubMed ID: 35600013
[TBL] [Abstract][Full Text] [Related]
49. Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.
Fodil S; Zafrani L
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207375
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic plasma exchange for thrombotic thrombocytopenic purpura with refractory thrombocytopenia.
Maloney N; Martin I; Szczepiorkowski ZM; Dunbar NM
J Clin Apher; 2018 Jun; 33(3):436-438. PubMed ID: 29270999
[TBL] [Abstract][Full Text] [Related]
51. Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center.
Martin SD; McGinnis E; Smith TW
Am J Clin Pathol; 2021 Nov; 156(6):1103-1112. PubMed ID: 34160013
[TBL] [Abstract][Full Text] [Related]
52. Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab.
Ditzel K; Mons DJ; Fijnheer R
Platelets; 2022 Apr; 33(3):484-485. PubMed ID: 33979560
[TBL] [Abstract][Full Text] [Related]
53. Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: Case series.
Albanell-Fernández M; Monge-Escartín I; Carcelero-San Martín E; Riu Viladoms G; Ruiz-Boy S; Lozano M; Soy D; Moreno-Castaño AB; Diaz-Ricart M; Cid J
Transfus Apher Sci; 2023 Jun; 62(3):103722. PubMed ID: 37169697
[TBL] [Abstract][Full Text] [Related]
54. Unmet needs in the management of immune-mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK-A modified-Delphi study.
Scully M; Dutt T; Lester W; Farrington E; Lockwood S; Perry R; Holmes S
EJHaem; 2022 Aug; 3(3):619-627. PubMed ID: 36051029
[TBL] [Abstract][Full Text] [Related]
55. Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura.
Bruzzese A; Vigna E; Terzi D; Greco S; Martino EA; Vangeli V; Mendicino F; Lucia E; Olivito V; Labanca C; Morelli R; Neri A; Morabito F; Zinno F; Mastroianni A; Gentile M
Hematol Rep; 2023 Jul; 15(3):448-453. PubMed ID: 37489376
[TBL] [Abstract][Full Text] [Related]
56. Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell trait successfully treated with caplacizumab.
Aggarwal V; Singer Z; Ledingham D; Othman I
Hematology; 2021 Dec; 26(1):590-593. PubMed ID: 34396933
[No Abstract] [Full Text] [Related]
57. Advances in the management of TTP.
Subhan M; Scully M
Blood Rev; 2022 Sep; 55():100945. PubMed ID: 35216839
[TBL] [Abstract][Full Text] [Related]
58. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.
Chung C
Ann Pharmacother; 2021 Mar; 55(3):330-343. PubMed ID: 32715723
[TBL] [Abstract][Full Text] [Related]
59. Role of the PLASMIC Score in the Management of Thrombotic Thrombocytopenic Purpura.
Vyas A; Isaac S; Kaur D; Yadav U
Cureus; 2023 Mar; 15(3):e36188. PubMed ID: 37065284
[TBL] [Abstract][Full Text] [Related]
60. [Pathogenesis and novel treatment of thrombotic thrombocytopenic purpura].
Matsumoto M
Rinsho Ketsueki; 2021; 62(5):480-485. PubMed ID: 34248125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
